{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,29]],"date-time":"2026-10-29T23:40:54Z","timestamp":1793317254184,"version":"4.5.0"},"reference-count":33,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2004,5,1]],"date-time":"2004-05-01T00:00:00Z","timestamp":1083369600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2004,5,1]],"date-time":"2004-05-01T00:00:00Z","timestamp":1083369600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["ard.eular.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Annals of the Rheumatic Diseases"],"published-print":{"date-parts":[[2004,5]]},"DOI":"10.1136\/ard.2003.013052","type":"journal-article","created":{"date-parts":[[2004,4,13]],"date-time":"2004-04-13T17:33:15Z","timestamp":1081877595000},"page":"508-516","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":504,"title":["Efficacy and safety of adalimumab as monotherapy in patients with rheumatoid arthritis for whom previous disease modifying antirheumatic drug treatment has failed"],"prefix":"10.1016","volume":"63","author":[{"given":"L B A","family":"van de Putte","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C","family":"Atkins","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M","family":"Malaise","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J","family":"Sany","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A S","family":"Russell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P L C M","family":"van Riel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"L","family":"Settas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J W","family":"Bijlsma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S","family":"Todesco","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M","family":"Dougados","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P","family":"Nash","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P","family":"Emery","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"N","family":"Walter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M","family":"Kaul","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S","family":"Fischkoff","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"H","family":"Kupper","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1136\/ard.2003.013052_bib1","doi-asserted-by":"crossref","first-page":"903","DOI":"10.1016\/S0140-6736(01)06075-5","article-title":"Rheumatoid arthritis","volume":"358","author":"Lee","year":"2001","journal-title":"Lancet"},{"key":"10.1136\/ard.2003.013052_bib2","doi-asserted-by":"crossref","first-page":"328","DOI":"10.1002\/art.10148","article-title":"Guidelines for the management of rheumatoid arthritis: 2002 update","volume":"46","year":"2002","journal-title":"Arthritis Rheum"},{"issue":"suppl III","key":"10.1136\/ard.2003.013052_bib3","doi-asserted-by":"crossref","first-page":"iii2","DOI":"10.1136\/ard.60.90003.iii2","article-title":"Updated consensus statement on tumour necrosis factor blocking agents for the treatment of rheumatoid arthritis and other rheumatic diseases (April 2001)","volume":"60","author":"Furst","year":"2001","journal-title":"Ann Rheum Dis"},{"key":"10.1136\/ard.2003.013052_bib4","doi-asserted-by":"crossref","first-page":"1105","DOI":"10.1016\/S0140-6736(94)90628-9","article-title":"Randomised double-blind comparison of chimeric monoclonal antibody to tumour necrosis factor alpha (cA2) versus placebo in rheumatoid arthritis","volume":"344","author":"Elliott","year":"1994","journal-title":"Lancet"},{"key":"10.1136\/ard.2003.013052_bib5","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1056\/NEJM199707173370301","article-title":"Treatment of rheumatoid arthritis with a recombinant human tumor necrosis factor receptor (p75)-Fc fusion protein","volume":"337","author":"Moreland","year":"1997","journal-title":"N Engl J Med"},{"key":"10.1136\/ard.2003.013052_bib6","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1002\/art.10697","article-title":"Adalimumab, a fully human anti-tumor necrosis factor alpha monoclonal antibody, for the treatment of rheumatoid arthritis in patients taking concomitant methotrexate: the ARMADA trial","volume":"48","author":"Weinblatt","year":"2003","journal-title":"Arthritis Rheum"},{"issue":"suppl 9","key":"10.1136\/ard.2003.013052_bib7","first-page":"S57","article-title":"Generation of fully human anti-TNF antibody D2E7 [abstract]","volume":"41","author":"Salfeld","year":"1998","journal-title":"Arthritis Rheum"},{"key":"10.1136\/ard.2003.013052_bib8","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1136\/ard.61.4.311","article-title":"Long term anti-tumour necrosis factor alpha monotherapy in rheumatoid arthritis: effect on radiological course and prognostic value of markers of cartilage turnover and endothelial activation","volume":"61","author":"den Broeder","year":"2002","journal-title":"Ann Rheum Dis"},{"key":"10.1136\/ard.2003.013052_bib9","doi-asserted-by":"crossref","first-page":"1700","DOI":"10.1016\/S0149-2918(03)80164-9","article-title":"Efficacy, pharmacokinetic, and safety assessment of adalimumab, a fully human anti-tumor necrosis factor-alpha monoclonal antibody, in adults with rheumatoid arthritis receiving concomitant methotrexate: a pilot study","volume":"25","author":"Weisman","year":"2003","journal-title":"Clin Ther"},{"key":"10.1136\/ard.2003.013052_bib10","doi-asserted-by":"crossref","first-page":"660","DOI":"10.1136\/ard.60.7.660","article-title":"Effects of treatment with a fully human anti-tumour necrosis factor \u03b1 monoclonal antibody on the local and systemic homeostasis of interleukin 1 and TNF \u03b1 in patients with rheumatoid arthritis","volume":"60","author":"Barrera","year":"2001","journal-title":"Ann Rheum Dis"},{"key":"10.1136\/ard.2003.013052_bib11","doi-asserted-by":"crossref","first-page":"430","DOI":"10.1093\/rheumatology\/41.4.430","article-title":"Drug survival, efficacy and toxicity of monotherapy with a fully human anti-tumour necrosis factor-alpha antibody compared with methotrexate in long-standing rheumatoid arthritis","volume":"41","author":"Barrera","year":"2002","journal-title":"Rheumatology (Oxford)"},{"key":"10.1136\/ard.2003.013052_bib12","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1002\/art.1780310302","article-title":"The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis","volume":"31","author":"Arnett","year":"1988","journal-title":"Arthritis Rheum"},{"key":"10.1136\/ard.2003.013052_bib13","doi-asserted-by":"crossref","first-page":"729","DOI":"10.1002\/art.1780360601","article-title":"The American College of Rheumatology preliminary core set of disease activity measures for rheumatoid arthritis clinical trials","volume":"36","author":"Felson","year":"1993","journal-title":"Arthritis Rheum"},{"key":"10.1136\/ard.2003.013052_bib14","first-page":"789","article-title":"The dimensions of health outcomes: the Health Assessment Questionnaire, disability and pain scales","volume":"9","author":"Fries","year":"1982","journal-title":"J Rheumatol"},{"issue":"suppl 2","key":"10.1136\/ard.2003.013052_bib15","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1093\/rheumatology\/35.suppl_2.4","article-title":"Development and validation of response criteria in rheumatoid arthritis: steps towards an international consensus on prognostic markers","volume":"35","author":"van Riel","year":"1996","journal-title":"Br J Rheumatol"},{"key":"10.1136\/ard.2003.013052_bib16","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1002\/art.1780390105","volume":"39","author":"van Gestel","year":"1996","journal-title":"Arthritis Rheum"},{"key":"10.1136\/ard.2003.013052_bib17","doi-asserted-by":"crossref","unstructured":"van Riel PLCM, van Gestel AM, Scott DL, on behalf of the EULAR Standing Committee for International Clinical Studies Including Therapeutic Trials. The EULAR handbook of clinical assessments in rheumatoid arthritis. Alpen an den Rijn. The Netherlands: Van Zuiden Communications, 2000.","DOI":"10.1136\/ard.60.11.1013"},{"key":"10.1136\/ard.2003.013052_bib18","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1002\/art.1780380107","article-title":"Modified disease activity scores that include twenty-eight-joint counts. Development and validation in a prospective longitudinal study of patients with rheumatoid arthritis","volume":"38","author":"Prevoo","year":"1995","journal-title":"Arthritis Rheum"},{"key":"10.1136\/ard.2003.013052_bib19","doi-asserted-by":"crossref","first-page":"916","DOI":"10.1136\/ard.49.11.916","article-title":"Judging disease activity in clinical practice in rheumatoid arthritis: first step in the development of a disease activity score","volume":"49","author":"van der Heijde","year":"1990","journal-title":"Ann Rheum Dis"},{"key":"10.1136\/ard.2003.013052_bib20","doi-asserted-by":"crossref","first-page":"942","DOI":"10.1002\/1529-0131(199805)41:5<942::AID-ART26>3.0.CO;2-B","article-title":"The original \u201cDAS\u201d and the \u201cDAS28\u201d are not interchangeable: comment on the articles by Prevoo et al [letter]","volume":"41","author":"van der Heijde","year":"1998","journal-title":"Arthritis Rheum"},{"key":"10.1136\/ard.2003.013052_bib21","unstructured":"Humira\u2122 (adalimumab) [package insert]. North Chicago, IL: Abbott Laboratories, 2004."},{"key":"10.1136\/ard.2003.013052_bib22","first-page":"561","article-title":"Criteria for clinically important changes in outcomes: development, scoring and evaluation of rheumatoid arthritis patient and trial profiles","volume":"20","author":"Goldsmith","year":"1993","journal-title":"J Rheumatol"},{"key":"10.1136\/ard.2003.013052_bib23","doi-asserted-by":"crossref","first-page":"1473","DOI":"10.1002\/1529-0131(200007)43:7<1473::AID-ANR9>3.0.CO;2-N","article-title":"Relationship between time-integrated C-reactive protein levels and radiologic progression in patients with rheumatoid arthritis","volume":"43","author":"Plant","year":"2000","journal-title":"Arthritis Rheum"},{"key":"10.1136\/ard.2003.013052_bib24","doi-asserted-by":"crossref","first-page":"2009","DOI":"10.1002\/1529-0131(200109)44:9<2009::AID-ART349>3.0.CO;2-L","article-title":"-The relationship between disease activity, joint destruction, and functional capacity over the course of rheumatoid arthritis","volume":"44","author":"Welsing","year":"2001","journal-title":"Arthritis Rheum"},{"key":"10.1136\/ard.2003.013052_bib25","doi-asserted-by":"crossref","first-page":"1932","DOI":"10.1016\/S0140-6736(99)05246-0","article-title":"Infliximab (chimeric anti-tumour necrosis factor \u03b1 monoclonal antibody) versus placebo in rheumatoid arthritis patients receiving concomitant methotrexate: a randomised phase III trial","volume":"354","author":"Maini","year":"1999","journal-title":"Lancet"},{"key":"10.1136\/ard.2003.013052_bib26","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1002\/art.10817","article-title":"Eligibility of patients in routine care for major clinical trials of anti-tumor necrosis factor \u03b1 agents in rheumatoid arthritis","volume":"48","author":"Sokka","year":"2003","journal-title":"Arthritis Rheum"},{"key":"10.1136\/ard.2003.013052_bib27","doi-asserted-by":"crossref","first-page":"478","DOI":"10.7326\/0003-4819-130-6-199903160-00004","article-title":"Etanercept therapy in rheumatoid arthritis: a randomized, controlled trial","volume":"130","author":"Moreland","year":"1999","journal-title":"Ann Intern Med"},{"key":"10.1136\/ard.2003.013052_bib28","doi-asserted-by":"crossref","first-page":"1168","DOI":"10.1136\/ard.2003.009563","article-title":"Efficacy and safety of the fully human anti-TNF-\u03b1 monoclonal antibody, adalimumab (D2E7), in DMARD-refractory patients with rheumatoid arthritis: a 12-week, phase II study","volume":"62","author":"van de Putte","year":"2003","journal-title":"Ann Rheum Dis"},{"issue":"uppl 9","key":"10.1136\/ard.2003.013052_bib29","first-page":"S171","article-title":"Incidence of injection-site reactions associated with adalimumab (D2E7) given subcutaneously for at least 6 months: a retrospective analysis of 4 phase II\/III clinical trials [abstract]","volume":"46","author":"Wells","year":"2002","journal-title":"Arthritis Rheum"},{"key":"10.1136\/ard.2003.013052_bib30","unstructured":"Enbrel\u00ae (etanercept) [package insert]. Seattle, WA: Immunex Corporation, 2002."},{"key":"10.1136\/ard.2003.013052_bib31","unstructured":"Kineret\u2122 (anakinra) [package insert]. Thousand Oaks, CA: Amgen, 2001."},{"key":"10.1136\/ard.2003.013052_bib32","doi-asserted-by":"crossref","first-page":"1098","DOI":"10.1056\/NEJMoa011110","article-title":"Tuberculosis associated with infliximab, a tumor necrosis factor alpha-neutralizing agent","volume":"345","author":"Keane","year":"2001","journal-title":"N Engl J Med"},{"key":"10.1136\/ard.2003.013052_bib33","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1093\/rheumatology\/keg263","article-title":"Serious bacterial infections in patients with rheumatoid arthritis under anti-TNF-alpha therapy","volume":"42","author":"Kroesen","year":"2003","journal-title":"Rheumatology (Oxford)"}],"container-title":["Annals of the Rheumatic Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S000349672408292X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S000349672408292X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/ard.2003.013052","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,1,5]],"date-time":"2025-01-05T08:13:44Z","timestamp":1736064824000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S000349672408292X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2004,5]]},"references-count":33,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2004,5]]}},"alternative-id":["S000349672408292X"],"URL":"https:\/\/doi.org\/10.1136\/ard.2003.013052","relation":{},"ISSN":["0003-4967"],"issn-type":[{"value":"0003-4967","type":"print"}],"subject":[],"published":{"date-parts":[[2004,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Efficacy and safety of adalimumab as monotherapy in patients with rheumatoid arthritis for whom previous disease modifying antirheumatic drug treatment has failed","name":"articletitle","label":"Article Title"},{"value":"Annals of the Rheumatic Diseases","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1136\/ard.2003.013052","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"simple-article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2004 Copyright 2004 by Annals of the Rheumatic Diseases, Published by Elsevier Inc. Published by Elsevier B.V. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}